Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917076 | 1.00 | ADORA3 (0.41) | ADORA3PTPN11TLR7NUDT1AHCY | |
| SCHEMBL21057496 | 1.00 | ADORA3 (0.41) | ADORA3PTPN11TLR7NUDT1AHCY | |
| SCHEMBL21057493 | 1.00 | ADORA3 (0.41) | ADORA3PTPN11TLR7NUDT1AHCY | |
| SCHEMBL21138158 | 0.85 | MAP4K4 (0.41) | ADORA3PTPN11TLR7AHCYKMT2A | |
| SCHEMBL21138161 | 0.85 | ADORA3 (0.43) | ADORA3PTPN11TLR7NUDT1AHCY | |
| SCHEMBL21138159 | 0.84 | ADORA3 (0.40) | ADORA3PTPN11TLR7NUDT1AHCY | |
| SCHEMBL21137449 | 0.82 | PTPN11 (0.34) | PTPN11KMT2A | |
| SCHEMBL19917168 | 0.81 | PTPN11 (0.39) | ADORA3PTPN11TLR7NUDT1AHCY | |
| SCHEMBL19917139 | 0.81 | PTPN11 (0.39) | ADORA3PTPN11TLR7NUDT1AHCY | |
| SCHEMBL21057479 | 0.78 | ADORA3 (0.38) | ADORA3PTPN11TLR7NUDT1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | ADORA3 1484/4885PTPN11 497/4885TLR7 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.